Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination.

Front Biosci (Schol Ed)

Department of Pharmaceutics and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.

Published: June 2010

AI Article Synopsis

  • Researchers are focusing on improving vaccine delivery using polymeric nanoparticles as adjuvants for mucosal immunization.
  • Conventional nanoparticles struggle to effectively target specific gut sites, leading to inadequate immune responses.
  • By coating poly(anhydride) nanoparticles with compounds like flagellin or mannosamine, enhanced immune responses are achieved, indicating a more effective Th1 response compared to typical Th2 responses from control nanoparticles.

Article Abstract

In the last years, many efforts have been directed toward the enhancement of vaccine delivery by using polymeric nanoparticles as adjuvants for mucosal immunization. However, conventional nanoparticles usually display a low capability to target specific sites within the gut and, thus, the elicited immune responses are not as high as necessary to offer the adequate protection to the host. To overcome these drawbacks, one possible strategy can be the association of nanoparticles with compounds involved in the colonization process of microorganisms. In this biomimetic context, two different examples are shown. In both cases, poly(anhydride) nanoparticles were coated with either flagellin from Salmonella Enteritidis or mannosamine. When administered by the oral route both types of ligand-coated nanoparticles induced stronger and more balanced serum titers of IgG2a and IgG1 than control nanoparticles which induced a typical Th2 response. This Th1 response enhancement may be related to the high tropism of both flagellin- and mannosylated-nanoparticles to the ileum and uptake by Peyer's patches rich in antigen presenting cells.

Download full-text PDF

Source
http://dx.doi.org/10.2741/s108DOI Listing

Publication Analysis

Top Keywords

polyanhydride nanoparticles
8
nanoparticles adjuvants
8
adjuvants mucosal
8
nanoparticles induced
8
nanoparticles
6
mucosal vaccination
4
vaccination years
4
years efforts
4
efforts directed
4
directed enhancement
4

Similar Publications

The heterogeneity of tumors and the lack of effective therapies have resulted in triple-negative breast cancer (TNBC) exhibiting the least favorable outcomes among breast cancer subtypes. TNBC is characterized by its aggressive nature, often leading to high rates of relapse, metastasis, and mortality. Niclosamide (Nic), an Food and Drug Administration-approved anthelmintic drug, has been repurposed for cancer treatment; however, its application for TNBC is hindered by significant challenges, including strong hydrophobicity, poor aqueous solubility, and low bioavailability.

View Article and Find Full Text PDF

With limited therapies and vaccines available, human respiratory syncytial virus (HRSV) has a significant negative health impact on all age groups but particularly on infants, young children, and older adults. Bovine respiratory syncytial virus (BRSV) is pathogenically and antigenically similar to HRSV. Building upon previous studies using a BRSV nanovaccine coencapsulating multiple proteins, this work demonstrates the development and comparative evaluation of a coencapsulated nanovaccine to a cocktail nanovaccine formulation composed of polyanhydride nanoparticles encapsulating BRSV postfusion (F) glycoprotein and CpG ODN 1668 coadjuvant delivered simultaneously with nanoparticles encapsulating BRSV attachment glycoprotein (G) and CpG ODN 1668.

View Article and Find Full Text PDF

Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2.

Acta Biomater

July 2024

Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA; Chemical & Biological Engineering, Iowa State University, Ames, IA 50011, USA. Electronic address:

While first generation SARS-CoV-2 vaccines were effective in slowing the spread and severity of disease during the COVID-19 pandemic, there is a need for vaccines capable of inducing durable and broad immunity against emerging variants of concern. Nanoparticle-based vaccines (i.e.

View Article and Find Full Text PDF

Influenza A virus (IAV) causes significant morbidity and mortality worldwide due to seasonal epidemics and periodic pandemics. The antigenic drift/shift of IAV continually gives rise to new strains and subtypes, aiding IAV in circumventing previously established immunity. As a result, there has been substantial interest in developing a broadly protective IAV vaccine that induces, durable immunity against multiple IAVs.

View Article and Find Full Text PDF

Degradable polymers (both biomacromolecules and several synthetic polymers) for biomedical applications have been promising very much in the recent past due to their low cost, biocompatibility, flexibility, and minimal side effects. Here, we present an overview with updated information on natural and synthetic degradable polymers where a brief account on different polysaccharides, proteins, and synthetic polymers viz. polyesters/polyamino acids/polyanhydrides/polyphosphazenes/polyurethanes relevant to biomedical applications has been provided.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!